STERIS plc reported solid third-quarter fiscal 2026 results, with total as-reported revenue growing 9% and constant currency organic revenue increasing 8% to reach $2.53 earnings per diluted share, a 9% increase over the prior year. Growth was driven by volume and 200 basis points of price, though profitability faced headwinds as gross margin declined 70 basis points to 43.9% and EBIT margin fell 40 basis points to 22.9%, primarily due to increased tariffs and inflation. Segment performance was robust, with Healthcare and AST growing 8% organically, led by an 11% increase in Healthcare services and a 103% surge in AST capital equipment revenue. Despite a $55 million annual run-rate impact from tariffs, management maintained its full-year guidance for 8-9% revenue growth and EPS of $10.00-$10.30, though they noted the higher end of the EPS range is less likely due to an incremental $10 million in tariff costs.
| Metric | Value | Change |
|---|---|---|
| Total Revenue Growth (As-reported) | 9% | +9% |
| Constant Currency Organic Revenue Growth | 8% | +8% |
| Earnings Per Diluted Share (EPS) | $2.53 | +9% |
| Gross Margin | 43.9% | -70 bps |
| EBIT Margin | 22.9% | -40 bps |
| Free Cash Flow (9 Months) | $7.368 billion | Improvement driven by earnings |
| Gross Debt to EBITDA | 1.2x | N/A |
STERIS is actively leveraging pricing and productivity to offset a significant $55 million annual run-rate impact from tariffs, with management detailing a multi-pronged mitigation strategy including shifting product movement, supplier negotiations, and facility efficiencies. This highlights the pricing power inherent in their 'utility-like' sterile processing and consumables business, allowing them to protect margins despite external cost pressures. The ability to maintain full-year EPS guidance amidst these escalating costs signals strong operational control and demand elasticity.
The Life Sciences segment is showing signs of a robust recovery, driven by a rebound in pharmaceutical capital expenditure and a favorable macro environment for US onshoring. Management noted a 'much better spot from a macro perspective' compared to a year ago, with specific strength in aseptic manufacturing capacity expansions in states like North Carolina and Pennsylvania. This recovery is supported by an 11% growth in consumables and a 7% increase in capital equipment backlog, indicating sustained momentum.
Management identified a strategic positive in the shift of surgical procedures to Ambulatory Surgical Centers (ASCs), driven by CMS proposals removing procedures from the inpatient-only list. CEO Daniel Carestio noted this shift creates 'new capacity demands' and requires 'higher degree of clinical support' where STERIS is uniquely positioned. This structural healthcare trend provides a durable growth driver for their Healthcare segment, offsetting broader capital spending moderation seen in other areas.
STERIS is executing structural changes to its go-to-market strategy in the EMEA region to drive more aggressive competition and integration. While Carestio noted this is a 'long process' and will take time to formulate, the commitment to these changes indicates a strategic priority to unlock value in international markets. This pivot could support future growth as they look to compete more effectively outside of their strong North American base.
Profitability is under pressure despite strong top-line growth, with gross margins declining 70 basis points and EBIT margins falling 40 basis points year-over-year. Management attributed this specifically to 'increased tariffs and inflation' which are currently outpacing the benefits of volume and price increases. With tariffs expected to step up further in Q4 and an incremental $10 million hit identified, margin expansion may remain elusive in the near term.
Management issued a clear warning regarding the fourth quarter, stating 'we do have a bit of a slowdown in the second half' and cautioning analysts against 'getting too excited.' This is compounded by a difficult comparison to last year's strong Q4, particularly in AST capital equipment, and an expectation that Healthcare services growth will decelerate from the teens to the 11% level seen in Q3. This sequential deceleration could spook investors expecting momentum to continue unabated.
The company's M&A pipeline appears dry, with CEO Daniel Carestio candidly admitting they have 'kissed a lot of frogs, and not a lot of them have turned out to be princesses.' With leverage low at 1.2x gross debt-to-EBITDA and no major transformative deals recently, the company is relying solely on organic growth. This lack of capital deployment could limit EPS acceleration or multiple expansion, especially if core growth slows as forecasted for Q4.
Healthcare capital equipment orders are down 1% year-to-date against a difficult comparison from last year's 'blowout' performance. While management argues their products are 'essential' and 'treated almost as a utility,' the order decline suggests some hesitation from hospital customers, potentially reflecting broader capital budget constraints or the impact of delayed purchasing decisions due to tariff uncertainty.
Overall: Management displayed a confident yet pragmatic demeanor, acknowledging significant tariff headwinds and inflationary pressures while emphasizing the resilience of their business model and the strength of their service revenue. They were transparent about a expected slowdown in the second half and the difficulty of finding accretive M&A targets, but remained steadfast in their long-term growth algorithm.
Confidence: MEDIUM - Management maintained full-year guidance despite rising costs, demonstrating confidence in their ability to mitigate tariffs through pricing and productivity. However, they explicitly cautioned against Q4 excitement and noted the higher end of EPS guidance is 'less likely,' while admitting to a lack of success in M&A ('kissed a lot of frogs'), which tempers the confidence level.
8% to 9% (As-reported)
7% to 8% (Constant Currency)
$10.00 to $10.30 (Higher end less likely)
$850 million
$375 million
Hedging & Uncertainty: Management employed frequent temporal hedges and qualifiers to manage expectations regarding the second half of the year. Phrases like 'a bit of a slowdown,' 'less likely,' and 'tough comparison' were used to temper Q4 optimism. They also used probabilistic language regarding M&A, noting they are 'looking' but haven't found suitable targets, and regarding tariffs, stating they are 'optimistic about our ability to continue to absorb those' rather than guaranteeing margin protection. This hedging suggests a cautious outlook where execution risks remain high due to external factors.
"We do have a bit of a slowdown in the second half. So and that would be my caution on getting too excited about the fourth quarter." - Karen Burton, Senior Vice President and CFO
"Although with $10 million more in anticipated tariffs, the higher end of that range is less likely." - Daniel A. Carestio, President and CEO
"We're looking, but at this point, we've kissed a lot of frogs, and not a lot of them have turned out to be princesses." - Daniel A. Carestio, President and CEO
"There's a wide variety of mitigation efforts going on and we are optimistic about our ability to continue to absorb those as we go forward." - Karen Burton, Senior Vice President and CFO
"I don't see a lot of downside or anything materially changing the market today." - Daniel A. Carestio, President and CEO
Analyst Sentiment: Analysts were focused on the sustainability of growth in the face of rising tariffs and the specific drivers behind the expected Q4 slowdown. There was skepticism regarding the lack of M&A activity given the strong balance sheet, and detailed inquiries into the volatility of AST service volumes.
Management Responses: Management was defensive but transparent regarding margins, explaining the specific mechanics of tariff impacts and mitigation. They were candid about the 'frog kissing' in M&A and provided granular detail on the monthly volatility within the quarter (weak October, strong December) to explain service trends.
Analysts pressed for details on the incremental $10 million tariff impact and whether the full $55 million run-rate was already annualized, seeking clarity on FY27 earnings power.
Discussion centered on the 'slowdown in the second half' and whether it was driven by macro weakness or difficult comparisons, with management emphasizing the latter.
Questions regarding the M&A pipeline were persistent, leading to the 'kissed a lot of frogs' admission, highlighting a gap between investor expectation for deals and management's reality.
Inquiries into the strength of Life Sciences capital and the potential benefits of US onshoring and regulatory changes (CMS proposals).
STERIS continues to demonstrate the resilience of its business model, delivering high single-digit organic growth and double-digit EPS growth despite a challenging inflationary and tariff environment. The company's strong service revenue (11% growth in Healthcare) and pricing power provide a solid floor, while the recovery in Life Sciences capital offers upside. However, the investment thesis is currently capped by margin compression (Gross and EBIT margins down YoY) and management's explicit guidance for a slowdown in Q4. Furthermore, the inability to deploy capital into M&A—despite a pristine balance sheet—limits the potential for multiple expansion or near-term acceleration. While the long-term algorithm remains intact, the risk/reward is balanced at current levels, warranting a Hold rating until margin expansion resumes or M&A catalysts emerge.
Management highlighted a $55 million annual run-rate impact from tariffs, specifically noting an incremental $10 million hit in the quarter. This is acting as a tax on earnings, forcing the company to rely on price increases and productivity improvements to maintain margins.
There is a noted positive trend in US onshoring of pharmaceutical manufacturing, specifically in aseptic processing. Management cited large capacity commitments in North Carolina and Pennsylvania, which is driving demand for AST capital equipment.
CMS proposals to remove procedures from the inpatient-only list are driving a shift to Ambulatory Surgical Centers (ASCs). STERIS views this as a net positive because ASCs require new capacity and higher levels of clinical support/sterilization services compared to large acute care facilities.